{"denoms":[{"counts":[{"groupId":"BG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"All patients that enrolled on the study and received treatment with T-BiRD are included in this analysis.","id":"BG000","title":"T-BiRD Therapy (All Patients)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"40","upperLimit":"82","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Stage 1A"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Stage 2A"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage 3A"}],"description":"The Durie Salmon Staging System was used to assess patients clinical status. Stage 1A is associated with a better outcome and a low tumor burden, stage 2A is associated with a intermediate outcome and tumor burden, and stage 3A is associated with a worse outcome and higher tumor burden. Patients are classified into each stage based on multiple criteria including hemoglobin and calcium values, disease burden, and renal function.\n\nThe Durie Salmon Staging System can be found here: https://www.themmrf.org/multiple-myeloma/prognosis/myeloma-stages/durie-salmon-staging-system/","paramType":"NUMBER","title":"Durie-Salmon Classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"standard risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"high risk"}],"description":"Cytogenetic analysis was done on all patients to determine if they were of standard or high risk. Cytogenetics were performed on bone marrow cultures.\n\nStandard risk was defined by the presence of one or more of the following on : t(11;14); hyperdiploidy; del 13q14 detected using florescence in situ hybridization (FISH); no abnormality High risk was defined by the presence of one or more of the following: del 17p; karyotype del 13q; amp 1q/del 1p; t(14;20); t(14;16); t(4;14)","paramType":"NUMBER","title":"Cytogenetics","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"IgA myeloma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"IgG myeloma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"light chain only myeloma"}],"paramType":"NUMBER","title":"Immunoglobulins","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"90% (or better)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"80%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"70%"}],"description":"Normal, no complaints = 100%; Able to carry on normal activities. Minor signs or symptoms of disease = 90%; Normal activity with effort = 80%; Care for self. Unable to carry on normal activity or to do active work = 70%; Requires occasional assistance, but able to care for most of his needs= 60% Requires considerable assistance \\& frequent medical care = 50%; Disabled. Requires special care \\& assistance = 40%; Severely disabled. Hospitalization indicated though death nonimminent = 30%; Very Sick, hospitalization necessary. Active supportive treatment necessary = 20%; moribund =10%; dead = 0%","paramType":"NUMBER","title":"karnofsky performance status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Stage III"}],"description":"Stage I ß2-M \\< 3.5 mg/dL and albumin =3.5 g/dL\n\nStage II Neither stage I nor stage III\n\nStage III ß2-M ≥ 5.5 mg/L","paramType":"NUMBER","title":"International Staging System Classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"9.1","upperLimit":"15.4","value":"11.95"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Hemoglobin at baseline (in g/dL)","unitOfMeasure":"g/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.5","upperLimit":"1.9","value":"0.85"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"serum creatinine at baseline (in mg/dL)","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"87","upperLimit":"383","value":"241"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"platelet count at baseline (in 1000/uL)","unitOfMeasure":"1000/uL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.9","upperLimit":"3.4","value":"3"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"absolute neutrophil count at baseline (in 1000/uL)","unitOfMeasure":"1000/uL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2.2","upperLimit":"4.4","value":"3.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"albumin at baseline (in mg/dL)","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"92","upperLimit":"280","value":"151"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"lactage dehydrogenase at baseline (U/L)","unitOfMeasure":"U/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.03","upperLimit":"10.3","value":"0.225"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"C-reactive protein at baseline (in mg/dL)","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.2","upperLimit":"7.6","value":"2.2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Beta-2 microglobulin at baseline (in mg/L)","unitOfMeasure":"mg/L"}]}